Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.
Clinical data | |
---|---|
Trade names | Maxair |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601096 |
Pregnancy category |
|
Routes of administration | Inhalational (MDI) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C12H20N2O3 |
Molar mass | 240.303 g·mol−1 |
3D model (JSmol) |
|
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
It was patented in 1971 and came into medical use in 1983.[1]
Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[2][3]
After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]